Sign in

CIK 0001395937

  • Large accelerated filer

Syndax Pharmaceuticals Inc

Sign in to watch
Ticker
SNDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
320162505
Phone
+1 781-419-1400
Business address
730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
  1. 4 Grant or award Director acquired 16,000 shares (grant or award)
  2. 4 Grant or award Director acquired 16,000 shares (grant or award)
  3. 4 Open-market sale Director sold 39,000 shares at an average $26.84 ($1,046,782)
  4. 4 Derivatives Options or other derivatives
  5. 3 Insider Initial Statement of Ownership
  6. 4 Open-market sale Chief Scientific Officer sold 25,000 shares at an average $25.04 ($626,025)
  7. 4 Open-market sale Director sold 29,899 shares at $25.90 ($774,411)
  8. 4 Open-market sale Chief Executive Officer sold 16,231 shares at $25.29 ($410,508)
  9. 4 Open-market sale Chief Executive Officer sold 33,769 shares at an average $25.02 ($844,890)
  10. 4 Open-market sale Director sold 4,101 shares at an average $25.06 ($102,777)
  11. 4 Open-market sale President, Head of R&D sold 173,988 shares at an average $23.11 ($4,020,056)
  12. 4 Open-market sale President, Head of R&D sold 279,420 shares at an average $23.64 ($6,604,327)
  13. 4 Open-market sale Director sold 78,815 shares at an average $24.08 ($1,897,988)
  14. 4 Open-market sale Chief Scientific Officer sold 25,000 shares at $25.04 ($625,893)
  15. 4 Open-market sale Director sold 24,000 shares at $23.02 ($552,382)
  16. 4 Open-market sale Chief Executive Officer sold 31,602 shares at $21.06 ($665,393)
  17. 4 Open-market sale Chief Executive Officer sold 15,109 shares at an average $21.07 ($318,407)
  18. 4 Open-market sale President, Head of R&D sold 62,292 shares at $19.00 ($1,183,430)
  19. 4 Grant or award Chief Financial Officer acquired 3,205 shares (grant or award)
  20. 3 Insider Initial Statement of Ownership

Page 5 of 13 · 259 filings